title: Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia.
abstract: Positron emission tomography (PET) imaging studies have shown that peak-dose dyskinesia is associated to abnormally high levels of synaptic dopamine (DA) in the caudate-putamen of dyskinetic L-DOPA-treated patients. High striatal extracellular DA levels have also been found in dyskinetic 6-OHDA-lesioned rats as compared to non-dyskinetic ones, suggesting that extracellular DA levels may play a key role in the induction of dyskinesia. In this article we review the evidences pointing to the serotonin system as the primary cause for the abnormally high levels of L-DOPA-derived extracellular DA in Parkinson's disease, and we discuss the feasibility of a therapeutic approach targeting this system.
authors.affiliation: Neurobiology Unit, Department of Experimental Medical Science, Lund University, BMC A11, Solvegatan 17, 22184 Lund, Sweden. manolocarta@unica.it
authors.forename: M
authors.initials: M
authors.lastname: Carta
authors.forename: E
authors.initials: E
authors.lastname: Bezard
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000009:adverse effects*; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D004409:Dyskinesia, Drug-Induced / Q000000981:diagnostic imaging / Q000473:pathology*; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D016627:Oxidopamine / Q000633:toxicity; D010300:Parkinson Disease / Q000188:drug therapy / Q000209:etiology; D049268:Positron-Emission Tomography; D017729:Presynaptic Terminals / Q000378:metabolism*; D051381:Rats; D059326:Serotonergic Neurons / Q000502:physiology; D012701:Serotonin / Q000378:metabolism*
chemical_list: D000978:Antiparkinson Agents; D012701:Serotonin; D007980:Levodopa; D016627:Oxidopamine; D004298:Dopamine